nct_id: NCT05660395
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2022-12-21'
study_start_date: '2023-08-28'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Loncastuximab Tesirine'
long_title: A Phase 1b Open-Label Study to Evaluate the Pharmacokinetics and Safety
  of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large
  B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
last_updated: '2025-07-16'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: ADC Therapeutics S.A.
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 56
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Male or female participants aged 18 years or older'
- '* Pathologic diagnosis of relapsed (disease that has recurred following a response)
  or refractory (disease that failed to respond to prior therapy) DLBCL not otherwise
  specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma
  (2016 World Health Organization classification) who have received at least one systemic
  treatment regimen'
- '* Measurable disease as defined by the 2014 Lugano Classification'
- '* Normal hepatic function or hepatic impairment as defined by the National Cancer
  Institute Organ Dysfunction Working Group hepatic impairment classification:'
- "* Arm A Normal hepatic function: bilirubin and aspartate aminotransferase (AST)\
  \ \u2264 upper limit of normal (ULN)"
- "* Arm B Moderate hepatic impairment: bilirubin \\> 1.5 \xD7 to 3 \xD7 ULN (any\
  \ AST)"
- "* Arm C Severe hepatic impairment: bilirubin \\> 3 \xD7 ULN (any AST)"
- '* ECOG performance status 0 to 2 for participants with normal hepatic function.
  ECOG 0 to 3 for participants with moderate or severe hepatic impairment'
- '* Adequate organ function'
- '* Women of childbearing potential (WOCBP)\* must agree to use a highly effective
  method of contraception from the time of giving informed consent until at least
  10 months after the last dose of study drug. Men with female partners who are of
  childbearing potential must agree to use a condom when sexually active or practice
  total abstinence from the time of the first dose until at least 7 months after the
  last dose of study drug.'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Previous therapy with loncastuximab tesirine
- Exclude - * Allogenic or autologous stem cell transplant within 60 days prior to
  start of study drug (C1D1)
- Exclude - * Human immunodeficiency virus (HIV) seropositive
- Exclude - * Serologic evidence of chronic hepatitis B virus (HBV) infection and
  unable or unwilling to receive standard prophylactic antiviral therapy or with detectable
  HBV viral load
- Exclude - * Serologic evidence of hepatitis C virus (HCV) infection without completion
  of curative treatment or with detectable HCV viral load
- Exclude - * History of Stevens-Johnson syndrome or toxic epidermal necrolysis
- Exclude - * Lymphoma with active central nervous system involvement at the time
  of screening, including leptomeningeal disease
- Exclude - * Breastfeeding or pregnant
- Exclude - * Significant medical comorbidities
- Exclude - * Major surgery, radiotherapy, chemotherapy, or other anti-neoplastic
  therapy, within 14 days prior to start of study drug (C1D1), except shorter if approved
  by the Sponsor
short_title: A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab
  Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma
  or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: ADC Therapeutics S.A.
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The primary objective of this study is to determine the recommended dosing
  regimen of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) or high-grade
  B-cell lymphoma (HGBCL) participants with moderate and severe hepatic impairment.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 'Arm A: Normal Hepatic Function'
      arm_internal_id: 0
      arm_description: 'Participants will receive loncastuximab tesirine 0.15 mg/kg
        once every 3 weeks (Q3W) for two cycles, then 0.075 mg/kg Q3W for subsequent
        cycles (1 cycle = 21 days).


        Participants who have a toxicity meeting the criteria for dose reduction will
        have subsequent doses reduced by 50%. If the toxicity recurs, subsequent doses
        must be reduced by an additional 50%. A maximum of 2 dose reductions are allowed.
        Participants who have a toxicity meeting the criteria for dose reduction following
        Cycle 2 will receive the protocol-specified dose of 50% of initiate dose for
        Cycle 3, i.e., they will not have an additional dose reduction for Cycle 3.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Loncastuximab Tesirine'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Arm B: Moderate Hepatic Impairment'
      arm_internal_id: 1
      arm_description: 'Participants will receive loncastuximab tesirine in a standard
        3+3 dose-escalation design. Initial dose will be 0.09 mg/kg Q3W for two cycles,
        then 0.045 mg/kg Q3W for subsequent cycles (1 cycle = 21 days). The highest
        dose possibly administered will be 0.15 mg/kg Q3W.


        Participants who have a toxicity meeting the criteria for dose reduction will
        have subsequent doses reduced by 50%. If the toxicity recurs, subsequent doses
        must be reduced by an additional 50%. A maximum of 2 dose reductions are allowed.
        Participants who have a toxicity meeting the criteria for dose reduction following
        Cycle 2 will receive the protocol-specified dose of 50% of initiate dose for
        Cycle 3, i.e., they will not have an additional dose reduction for Cycle 3.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Loncastuximab Tesirine'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Arm C: Severe Hepatic Impairment'
      arm_internal_id: 2
      arm_description: 'Participants will receive loncastuximab tesirine in a standard
        3+3 dose-escalation design. Initial dose will be 0.09 mg/kg Q3W for two cycles,
        then 0.045 mg/kg Q3W for subsequent cycles (1 cycle = 21 days). The highest
        dose possibly administered will be 0.15 mg/kg Q3W.


        Participants who have a toxicity meeting the criteria for dose reduction will
        have subsequent doses reduced by 50%. If the toxicity recurs, subsequent doses
        must be reduced by an additional 50%. A maximum of 2 dose reductions are allowed.
        Participants who have a toxicity meeting the criteria for dose reduction following
        Cycle 2 will receive the protocol-specified dose of 50% of initiate dose for
        Cycle 3, i.e., they will not have an additional dose reduction for Cycle 3.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Loncastuximab Tesirine'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        disease_status:
        - Recurrent
        - Refractory
        oncotree_primary_diagnosis: Lymphoid Neoplasm
